Clinical Research, Pharma & Healthcare FinancingIncyte Announces Phase 3 Results for Ruxolitinib Cream in PNBusiness WireMarch 10, 2025March 18, 2025 by Business WireMarch 10, 2025March 18, 20250104 Full data from the Phase 3 TRuE-PN1 study, presented today in a late-breaking oral presentation, showed the study met all primary and key secondary endpoints...
